Lv1
20 积分 2023-05-19 加入
Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
4小时前
待确认
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias
5小时前
已完结
Advances in menin inhibition in acute myeloid leukemia
5小时前
已完结
Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models
3天前
已完结
Machine Learning for ADMET Prediction: A Systematic Review of Models and Validation
15天前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
16天前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
23天前
已完结
Discovery of Potent and Orally Bioavailable Novel Cluster of Differentiation 38 (CD38) Small Molecule Inhibitors
1个月前
已完结
MolGpka: A Web Server for Small Molecule pKa Prediction Using a Graph-Convolutional Neural Network
2个月前
已完结
Multitask Learning for Membrane Permeability Prediction across Assays with Prediction Reliability Assessment
2个月前
已完结
皖公网安备34019202002308
